VivoSense Raises $25 Million to Collect Wearable Data for Clinical Drug Trials

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

VivoSense Raises $25 Million to Collect Wearable Data for Clinical Drug Trials
Image courtesy of VivoSense

As the CEO of Sarepta Therapeutics from 2011 to 2015, Chris Garabedian led a biotech firm striving to find cures for rare diseases. But because such diseases usually affect only a small population, it became difficult to collect a robust dataset on patients during clinical trials—the lengthy and rigorous process by which drugs are able to receive Food and Drug Administration approval for safety and efficacy.

At the time, Garabedian wanted to see if Sarepta could collect more data on its trial patients through the use of wearable sensors—but in 2011, as he recalled to dot.LA, it was hard to find technology that could collect and organize that kind of information.

More than a decade later, as the portfolio manager of an early-stage biotech investment fund, Garabedian is backing a company that’s looking to do just that.

VivoSense, a Newport Beach-based biometric data company, announced on Wednesday that it has raised $25 million in Series A funding co-led by Garabedian’s Perceptive Xontogeny Venture Fund and the Debiopharm Innovation Fund, the corporate venture arm of Swiss biopharma company Debiopharm. The new funding takes VivoSense to a total of $27 million raised to date..

VivoSense CEO Dudley Tabakin.

Photo courtesy of VivoSense

The startup collects and organizes data from biometric sensors that are used during clinical trials. The sensors track data like heart rate, breathing and bone density as participants use a drug, and provide valuable information to help understand how a drug affects a patient’s day-to-day life.

“There was a need to analyze that data and start using it to develop outcome measures that could be used in clinical trials by pharmaceutical companies,” VivoSense co-founder and CEO Dudley Tabakin told dot.LA.

The Series A funding will go towards building out VivoSense’s data technology for clinical trials, as well as for physicians who rely on remote monitoring technology to track patients who cannot visit the doctor as frequently.

“Pharmaceutical companies and biotechs should be proactively thinking about incorporating these types of methods into their clinical trials,” Garabedian told dot.LA. “It could make the difference between an approved drug or not.”

In 2020, the FDA revised its clinical trial standards after the pandemic kept people from leaving their homes, opening the door to a slew of companies tackling every aspect of a remote and distributed clinical trial system that still needs to be painstakingly accurate. El Segundo-based Lightship raised $40 million in September to create a fully-integrated virtual clinical trial setting, while Culver City-based Science 37 has received backing from large pharma companies like Thousand Oaks-based Amgen to make it easier for clinical trial conductors to find patients in a socially distant world.

The FDA’s move opened the door for more diversity in clinical trials, which is needed to accurately evaluate the safety of drugs. The agency has also been pushing for companies to collect more lifestyle data that “are meaningful to the patient”—like how they will react to a drug based on their sleep schedule, diet and health—rather than strict biologics, Tabakin said.

Subscribe to our newsletter to catch every headline.


A Lawsuit Blames ‘Defective’ TikTok Algorithm for Children’s Deaths

Christian Hetrick

Christian Hetrick is dot.LA's Entertainment Tech Reporter. He was formerly a business reporter for the Philadelphia Inquirer and reported on New Jersey politics for the Observer and the Press of Atlantic City.

A Lawsuit Blames ‘Defective’ TikTok Algorithm for Children’s Deaths
Image by Shutterstock

Social media companies are often accused of hosting harmful content, but it’s very hard to successfully sue them. A federal law known as Section 230 largely protects the platforms from legal responsibility for hate speech, slander and misinformation created by its users.

But a new lawsuit blaming TikTok for the deaths of two children is taking a different approach. Rather than accuse the company of failing to moderate content, the complaint claims TikTok is a dangerous and defective product.

Read moreShow less

Meet the Startups Joining the Long Beach Accelerator's New Cohort

Deirdre Newman
Deirdre Newman is an Orange County-based journalist, editor and author and the founder of Inter-TECH-ion, an independent media site that reports on tech at the intersection of diversity and social justice.
Long Beach harbor
Photo by Sean Pavone/ Shutterstock

Long Beach has a long history of innovation. It’s one of the densest aerospace hubs on the West Coast. There’s a vital port there, and the city is home to several tech industries—including health care, space tech and cybersecurity. That, along with its colleges and universities, have made Long Beach an enticing destination for entrepreneurs.

It’s within this environment that the Long Beach Accelerator sprouted in 2019 and has grown since. To date, the accelerator has cycled 20 companies through its four-month program, helping them raise a total of over $12 million.

Read moreShow less